NEW HAMPTON, N.Y., July 30, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today record second quarter net earnings of $22.7 million for 2021, compared to net earnings of $21.1 million for the second quarter 2020, adjusted net earnings(a) of $30.4 million, compared to $27.6 million in the prior year quarter, and adjusted EBITDA(a) of $50.1 million, compared to $43.9 million in the prior year quarter.
Second Quarter 2021 Financial Highlights:
- Net sales were $202.4 million, an increase of $29.0 million, or 16.7%, compared to the prior year quarter, with record sales in all three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
- Adjusted EBITDA was $50.1 million, an increase of $6.3 million, or 14.3%, from the prior year.
- GAAP net earnings were $22.7 million, an increase of $1.6 million, or 7.6% from the prior year. These net earnings resulted in GAAP earnings per share of $0.70.
- Adjusted net earnings were $30.4 million, an increase of $2.8 million or 10.3% from the prior year. These adjusted net earnings resulted in adjusted earnings per share(a) of $0.93.
- The effective tax rate of 24.3% was 561 basis point higher than the prior year tax rate of 18.7%.
- Quarterly cash flows from operations were $35.8 million for the second quarter 2021, with quarterly free cash flow(a) of $28.4 million.
Recent Highlights:
- In June, Balchem’s Board of Directors elected Ms. Kathy Fish to fill a vacancy on the Board. Ms. Fish recently retired from the position of Chief Research, Development and Innovation Officer at The Procter & Gamble Company (NYSE: PG). Over a long career at Procter & Gamble, Ms. Fish held various roles within the research and development function of increasing responsibility before leading the function from 2014 to 2020. Ms. Fish brings to the Balchem Board important new product development and direct to consumer expertise, along with her international business acumen and experience in driving a growth culture. Ms. Fish will serve on the Corporate Governance & Nominating Committee.
- We released our annual Sustainability Report in April in support of our Environmental, Social, and Corporate Governance ideals. We also disclosed our 2030 goals around emissions reduction and water conservation focused on reducing both greenhouse gas emissions and water use by 25%. We are committed to operating with excellence as strong stewards of our stakeholders while providing innovative solutions for the health and nutritional needs of the world.
- In May, our Verona, Missouri plant experienced a flash flood event as a result of very localized storms in the southwest part of the state. The plant was shut down for several weeks as we repaired affected equipment, cleaned the site, and safely re-started activities. The negative direct financial impact to the quarter was approximately $3.8 million, primarily due to the write off of damaged inventory and the costs associated with external service providers used for the clean-up efforts. Customer requirements were largely satisfied through inventory on hand and by leveraging alternate and redundant manufacturing capabilities across our supply chain. The manufacturing site is now fully operational and we have filed a related insurance claim with the expectation to partially offset these expenses with future insurance recoveries.
- Strong cash flows in the second quarter enabled the company to make repayments on its revolving debt of $30.0 million, lowering net debt to $43.7 million, with an overall leverage ratio on a net debt basis of 0.2.
Ted Harris, Chairman, CEO, and President of Balchem said, “The second quarter of 2021 was another strong quarter for Balchem. We delivered exceptional performance in a dynamic market environment and we continued to see strong demand for our products and services with double-digit sales growth in all three of our business segments versus the prior year's quarter, as well as sequential growth in all three segments.”
Mr. Harris added, “While we experienced a challenging and unexpected event this quarter with the flash flood at one of our manufacturing plants, I am extremely proud of how the Balchem team responded to the event, safely returned the plant to operations within the quarter, and worked tirelessly to satisfy customer needs through our broader supply chain capabilities. Our ability to deliver these strong financial results while managing through the flash flood event along with the other macro-economic challenges we have been facing, is once again a testament to the resilience and strength of our business model and the Balchem team.”
Results for Period Ended June 30, 2021 (unaudited)
(Dollars in thousands, except per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net sales | $ | 202,365 | $ | 173,355 | $ | 388,021 | $ | 347,791 | ||||||||
| Gross margin | 59,447 | 55,380 | 118,174 | 110,711 | ||||||||||||
| Operating expenses | 28,854 | 28,463 | 57,006 | 57,516 | ||||||||||||
| Earnings from operations | 30,593 | 26,917 | 61,168 | 53,195 | ||||||||||||
| Other expense | 574 | 944 | 1,166 | 2,732 | ||||||||||||
| Earnings before income tax expense | 30,019 | 25,973 | 60,002 | 50,463 | ||||||||||||
| Income tax expense | 7,288 | 4,848 | 13,860 | 9,570 | ||||||||||||
| Net earnings | $ | 22,731 | $ | 21,125 | $ | 46,142 | $ | 40,893 | ||||||||
| Diluted net earnings per common share | $ | 0.70 | $ | 0.65 | $ | 1.41 | $ | 1.26 | ||||||||
| Adjusted EBITDA(a) | $ | 50,145 | $ | 43,885 | $ | 95,869 | $ | 86,256 | ||||||||
| Adjusted net earnings(a) | $ | 30,397 | $ | 27,562 | $ | 58,844 | $ | 54,003 | ||||||||
| Adjusted net earnings per common share(a) | $ | 0.93 | $ | 0.85 | $ | 1.80 | $ | 1.66 | ||||||||
| Shares used in the calculations of diluted and adjusted net earnings per common share | 32,651 | 32,470 | 32,653 | 32,492 | ||||||||||||
| (a) | See “Non-GAAP Financial Information” for a reconciliation of GAAP and non-GAAP financial measures. |
Financial Results for the Second Quarter of 2021:
The Human Nutrition & Health segment generated all-time record quarterly sales of $111.5 million, an increase of $14.0 million or 14.4% compared to the prior year quarter. The increase was driven both by strong sales growth within food and beverage markets as well as higher sales within the Minerals and Nutrients business. This segment generated quarterly earnings from operations of $19.0 million, an increase of $3.5 million or 22.7%, compared to $15.5 million in the prior year quarter, primarily due to the aforementioned higher sales and overall manufacturing efficiencies, partially offset by higher raw material and distribution costs and the costs associated with the recovery from the flash flood event that we experienced at our Verona, Missouri manufacturing site. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets of $4.3 million and $4.8 million for the second quarter of 2021 and 2020, respectively, and the expense related to the flash flood event of $2.1 million for the second quarter of 2021, adjusted earnings from operations(a) for this segment were $25.3 million, compared to $20.3 million in the prior year quarter.
The Animal Nutrition & Health segment generated all-time record quarterly sales of $54.5 million, an increase of $8.1 million or 17.6% compared to the prior year quarter. The increase was primarily the result of higher sales in both Monogastric and Ruminant animal markets and a favorable impact related to changes in foreign currency exchange rates. Second quarter earnings from operations for this segment of $3.6 million decreased $2.9 million or 44.6% compared to $6.4 million in the prior year quarter, primarily due to increases in raw material and distribution costs and the costs associated with the recovery from the flash flood event. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets of $0.2 million for both the second quarter of 2021 and 2020, and the expense related to the flash flood event of $1.4 million for the second quarter of 2021, adjusted earnings from operations for this segment were $5.2 million compared to $6.6 million in the prior year quarter.
The Specialty Products segment generated all-time record quarterly sales of $34.0 million, an increase of $5.8 million or 20.7% compared to the prior year quarter, primarily due to higher sales for products in both the plant nutrition business and the medical device sterilization market. Second quarter earnings from operations for this segment were $9.7 million, versus $8.0 million in the prior year comparable quarter, an increase of $1.7 million or 21.5%, primarily due to the aforementioned higher sales, partially offset by increases in raw material and distribution costs. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets for the second quarter of 2021 and 2020 of $1.3 million and $1.6 million, respectively, and the expense related to the flash flood event of $0.2 million for the second quarter of 2021, adjusted earnings from operations for this segment were $11.2 million, compared to $9.6 million in the prior year quarter.
All-time record consolidated gross margin for the quarter ended June 30, 2021 of $59.4 million increased by $4.1 million or 7.3%, compared to $55.4 million for the prior year comparable period. Gross margin as a percentage of sales was 29.4% as compared to 31.9% in the prior year period, a decrease of 257 basis points, primarily due to a significant increase in certain raw material and distribution costs and the costs associated with the recovery from the flash flood event, partially offset by favorable mix and overall manufacturing efficiencies. Operating expenses of $28.9 million for the quarter increased $0.4 million from the prior year comparable quarter, primarily due to an increase in certain higher compensation-related costs, partially offset by the prior year being negatively impacted by a goodwill impairment charge related to business formerly included in the Industrial Products segment, and a decrease in transaction and integration costs. Excluding non-cash operating expenses associated with amortization of intangible assets of $5.9 million, operating expenses were $22.9 million, or 11.3% of sales.
Interest expense was $0.6 million in the second quarter of 2021. Our effective tax rates for the three months ended June 30, 2021 and 2020 were 24.3% and 18.7%, respectively. The increase in the effective tax rate from the prior year was primarily due to a reduction in certain tax credits and lower tax benefits from stock-based compensation.
For the quarter ended June 30, 2021, cash flows provided by operating activities were $35.8 million, and free cash flow was $28.4 million. The $186.5 million of net working capital on June 30, 2021 included a cash balance of $79.9 million, which reflects repayments of the revolving debt of $30.0 million, and capital expenditures and intangible assets acquired of $7.4 million.
Ted Harris said, “The second quarter of 2021 was another solid quarter for Balchem. While we faced macro-economic challenges, particularly from significantly higher raw material costs as well as complexities associated with logistical disruptions, we stepped up to meet these challenges and once again delivered a strong financial performance, while at the same time continuing to progress our strategic growth initiatives.”
Quarterly Conference Call
A quarterly conference call will be held on Friday, July 30, 2021, at 11:00 AM Eastern Time (ET) to review second quarter 2021 results. Ted Harris, Chairman of the Board, CEO and President and Martin Bengtsson, CFO will host the call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five minutes prior to the scheduled start time of the conference call. The conference call will be available for replay two hours after the conclusion of the call through end of day Friday, August 13, 2021. To access the replay of the conference call, dial 1-877-660-6853 (local dial-in 1-201-612-7415), and use conference ID #13721555.
Segment Information
Balchem Corporation reports three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
Forward-Looking Statements
This release contains forward-looking statements, which reflect Balchem’s expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations, including risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2020. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date.
Selected Financial Data (unaudited)
($ in 000’s)
| Business Segment Net Sales: | Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Human Nutrition & Health | $ | 111,471 | $ | 97,428 | $ | 215,987 | $ | 192,936 | ||||||||
| Animal Nutrition & Health | 54,481 | 46,344 | 105,629 | 94,985 | ||||||||||||
| Specialty Products | 34,022 | 28,194 | 62,030 | 56,190 | ||||||||||||
| Other and Unallocated (b) | 2,391 | 1,389 | 4,375 | 3,680 | ||||||||||||
| Total | $ | 202,365 | $ | 173,355 | $ | 388,021 | $ | 347,791 | ||||||||
| Business Segment Earnings Before Income Taxes: | Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Human Nutrition & Health | $ | 19,021 | $ | 15,497 | $ | 38,711 | $ | 27,632 | ||||||||
| Animal Nutrition & Health | 3,561 | 6,430 | 8,617 | 14,474 | ||||||||||||
| Specialty Products | 9,729 | 8,008 | 16,918 | 15,994 | ||||||||||||
| Other and Unallocated (b) | (1,718 | ) | (3,018 | ) | (3,078 | ) | (4,905 | ) | ||||||||
| Interest and other expense | (574 | ) | (944 | ) | (1,166 | ) | (2,732 | ) | ||||||||
| Total | $ | 30,019 | $ | 25,973 | $ | 60,002 | $ | 50,463 | ||||||||
| (b) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $466 and $700 for the three and six months ended June 30, 2021, respectively, and $746 and $2,018 for the three and six months ended June 30, 2020, respectively (refer to note 4 for descriptions of these charges), and (ii) Unallocated amortization expense of $604 and $1,208 for the three and six months ended June 30, 2021, respectively, and $405 and $806 for the three and six months ended June 30, 2020, respectively, related to an intangible asset in connection with a company-wide ERP system implementation. | ||||||||||||||||
| Selected Balance Sheet Items | ||||||||
| (Dollars in thousands) | June 30, 2021 | December 31, 2020 | ||||||
| (unaudited) | ||||||||
| Cash and Cash Equivalents | $ | 79,902 | $ | 84,571 | ||||
| Accounts Receivable, net | 113,782 | 98,214 | ||||||
| Inventories | 78,333 | 70,620 | ||||||
| Other Current Assets | 15,246 | 13,483 | ||||||
| Total Current Assets | 287,263 | 266,888 | ||||||
| Property, Plant & Equipment, net | 228,289 | 228,096 | ||||||
| Goodwill | 527,148 | 529,463 | ||||||
| Intangible Assets with Finite Lives, net | 108,253 | 121,660 | ||||||
| Right of Use Assets | 9,575 | 8,410 | ||||||
| Other Assets | 13,078 | 11,326 | ||||||
| Total Assets | $ | 1,173,606 | $ | 1,165,843 | ||||
| Current Liabilities | $ | 100,759 | $ | 94,428 | ||||
| Revolving Loan | 123,569 | 163,569 | ||||||
| Deferred Income Taxes | 51,883 | 51,359 | ||||||
| Derivative Liabilities | 7,662 | 11,658 | ||||||
| Long-Term Obligations | 20,091 | 16,596 | ||||||
| Total Liabilities | 303,964 | 337,610 | ||||||
| Stockholders' Equity | 869,642 | 828,233 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 1,173,606 | $ | 1,165,843 | ||||
Balchem Corporation
Condensed Consolidated Statements of Cash Flows
(Dollars in thousands)
(unaudited)
| Six Months Ended June 30, | ||||||||
| 2021 | 2020 | |||||||
| Cash flows from operating activities: | ||||||||
| Net earnings | $ | 46,142 | $ | 40,893 | ||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 24,463 | 25,294 | ||||||
| Stock compensation expense | 5,914 | 4,501 | ||||||
| Other adjustments | (391 | ) | 2,697 | |||||
| Changes in assets and liabilities | 261 | (6,205 | ) | |||||
| Net cash provided by operating activities | 76,389 | 67,180 | ||||||
| Cash flows from investing activities: | ||||||||
| Capital expenditures and intangible assets acquired | (13,760 | ) | (13,265 | ) | ||||
| Proceeds from sale of assets | 240 | 22 | ||||||
| Purchase of convertible note | — | (350 | ) | |||||
| Net cash used in investing activities | (13,520 | ) | (13,593 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from revolving loan | 5,000 | 10,000 | ||||||
| Principal payments on revolving loan | (45,000 | ) | (40,000 | ) | ||||
| Principal payments on acquired debt | (78 | ) | — | |||||
| Proceeds from stock options exercised | 3,886 | 6,802 | ||||||
| Dividends paid | (18,700 | ) | (16,704 | ) | ||||
| Purchase of treasury stock | (10,835 | ) | (3,025 | ) | ||||
| Net cash used in financing activities | (65,727 | ) | (42,927 | ) | ||||
| Effect of exchange rate changes on cash | (1,811 | ) | 75 | |||||
| (Decrease) increase in cash and cash equivalents | (4,669 | ) | 10,735 | |||||
| Cash and cash equivalents, beginning of period | 84,571 | 65,672 | ||||||
| Cash and cash equivalents, end of period | $ | 79,902 | $ | 76,407 | ||||
Non-GAAP Financial Information
In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures disclosed by the company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain unallocated equity compensation, and certain one-time or unusual transactions. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Management believes that these non-GAAP measures provide useful information about the Company's core operating results and thus are appropriate to enhance the overall understanding of the Company's past financial performance and its prospects for the future. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted per diluted share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, and free cash flow. EBITDA is defined as earnings before interest, other expense/income, taxes, depreciation and amortization. Adjusted EBITDA is defined as earnings before interest, other expense/income, taxes, depreciation, amortization, stock-based compensation, transaction and integration costs, indemnification settlements, legal settlements, ERP implementation costs, unallocated legal fees, the fair valuation of acquired inventory, goodwill impairment, restructuring costs, and the expense related to a flash flood event. Adjusted income tax expense is defined as income tax expense adjusted for the impact of ASU 2016-09. Free cash flow is defined as net cash provided by operating activities less capital expenditures and capitalized ERP implementation costs.
Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
Table 1
Reconciliation of Non-GAAP Measures to GAAP
(Dollars in thousands, except per share data)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Reconciliation of adjusted gross margin | ||||||||||||||||
| GAAP gross margin | $ | 59,447 | $ | 55,380 | $ | 118,174 | $ | 110,711 | ||||||||
| Expense related to a flash flood event (1) | 3,765 | — | 3,765 | — | ||||||||||||
| Inventory valuation adjustment (2) | — | — | — | 208 | ||||||||||||
| Amortization of intangible assets and finance lease (3) | 339 | 742 | 828 | 1,466 | ||||||||||||
| Adjusted gross margin | $ | 63,551 | $ | 56,122 | $ | 122,767 | $ | 112,385 | ||||||||
| Reconciliation of adjusted earnings from operations | ||||||||||||||||
| GAAP earnings from operations | $ | 30,593 | $ | 26,917 | $ | 61,168 | $ | 53,195 | ||||||||
| Expense related to a flash flood event (1) | 3,765 | — | 3,765 | — | ||||||||||||
| Inventory valuation adjustment (2) | — | — | — | 208 | ||||||||||||
| Amortization of intangible assets and finance lease (3) | 6,282 | 6,985 | 12,818 | 13,964 | ||||||||||||
| Transaction and integration costs, ERP implementation costs, and unallocated legal fees (4) | 466 | 746 | 700 | 2,018 | ||||||||||||
| Goodwill impairment (5) | — | 1,228 | — | 1,228 | ||||||||||||
| Adjusted earnings from operations | $ | 41,106 | $ | 35,876 | $ | 78,451 | $ | 70,613 | ||||||||
| Reconciliation of adjusted net earnings | ||||||||||||||||
| GAAP net earnings | $ | 22,731 | $ | 21,125 | $ | 46,142 | $ | 40,893 | ||||||||
| Expense related to a flash flood event (1) | 3,765 | — | 3,765 | — | ||||||||||||
| Inventory valuation adjustment (2) | — | — | — | 208 | ||||||||||||
| Amortization of intangible assets and finance lease (3) | 6,352 | 7,056 | 12,959 | 14,105 | ||||||||||||
| Transaction and integration costs, ERP implementation costs, and unallocated legal fees (4) | 466 | 746 | 700 | 2,018 | ||||||||||||
| Goodwill impairment (5) | — | 1,228 | — | 1,228 | ||||||||||||
| Income tax adjustment (6) | (2,917 | ) | (2,593 | ) | (4,722 | ) | (4,449 | ) | ||||||||
| Adjusted net earnings | $ | 30,397 | $ | 27,562 | $ | 58,844 | $ | 54,003 | ||||||||
| Adjusted net earnings per common share - diluted | $ | 0.93 | $ | 0.85 | $ | 1.80 | $ | 1.66 | ||||||||
The following table sets forth a reconciliation of Net Income calculated using amounts determined in accordance with GAAP to EBITDA and to Adjusted EBITDA for the three and six months ended June 30, 2021 and 2020.
Table 2
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net income - as reported | $ | 22,731 | $ | 21,125 | $ | 46,142 | $ | 40,893 | ||||||||
| Add back: | ||||||||||||||||
| Provision for income taxes | 7,288 | 4,848 | 13,860 | 9,570 | ||||||||||||
| Other expense | 574 | 944 | 1,166 | 2,732 | ||||||||||||
| Depreciation and amortization | 12,029 | 12,674 | 24,322 | 25,153 | ||||||||||||
| EBITDA | 42,622 | 39,591 | 85,490 | 78,348 | ||||||||||||
| Add back certain items: | ||||||||||||||||
| Non-cash compensation expense related to equity awards | 3,292 | 2,320 | 5,914 | 4,454 | ||||||||||||
| Expense related to a flash flood event (1) | 3,765 | — | 3,765 | — | ||||||||||||
| Inventory valuation adjustment (2) | — | — | — | 208 | ||||||||||||
| Transaction and integration costs, ERP implementation costs, and unallocated legal fees (4) | 466 | 746 | 700 | 2,018 | ||||||||||||
| Goodwill impairment (5) | — | 1,228 | — | 1,228 | ||||||||||||
| Adjusted EBITDA | $ | 50,145 | $ | 43,885 | $ | 95,869 | $ | 86,256 | ||||||||
The following table sets forth a reconciliation of our GAAP effective income tax rate to our non-GAAP effective income tax rate for the three and six months ended June 30, 2021 and 2020.
Table 3
(unaudited)
| Three Months Ended June 30, | ||||||||||||||
| 2021 | Effective Tax Rate | 2020 | Effective Tax Rate | |||||||||||
| GAAP Income Tax Expense | $ | 7,288 | 24.3 | % | $ | 4,848 | 18.7 | % | ||||||
| Impact of ASU 2016-09 (7) | 291 | 673 | ||||||||||||
| Adjusted Income Tax Expense | $ | 7,579 | 25.3 | % | $ | 5,521 | 21.3 | % | ||||||
| Six Months Ended June 30, | ||||||||||||||
| 2021 | Effective Tax Rate | 2020 | Effective Tax Rate | |||||||||||
| GAAP Income Tax Expense | $ | 13,860 | 23.1 | % | $ | 9,570 | 19.0 | % | ||||||
| Impact of ASU 2016-09 (7) | 540 | 830 | ||||||||||||
| Adjusted Income Tax Expense | $ | 14,400 | 24.0 | % | $ | 10,400 | 20.6 | % | ||||||
The following table sets forth a reconciliation of net cash provided by operating activities to free cash flow for the three and six months ended June 30, 2021 and 2020.
Table 4
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net cash provided by operating activities | $ | 35,782 | $ | 44,615 | $ | 76,389 | $ | 67,180 | ||||||||
| Capital expenditures and capitalized ERP implementation costs | (7,372 | ) | (7,595 | ) | (13,547 | ) | (12,747 | ) | ||||||||
| Free cash flow | $ | 28,410 | $ | 37,020 | $ | 62,842 | $ | 54,433 | ||||||||
| (1) Expense related to a flash flood event: Expenses related to a flash flood event at our Verona, Missouri manufacturing site are expensed in our GAAP financial statements. We believe that excluding these costs from our non-GAAP financial measures is useful to investors because such expense is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (2) Inventory valuation adjustment: Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of inventory reflects the acquired company’s cost of manufacturing plus a portion of the expected profit margin. The non-GAAP adjustment to our cost of sales excludes the expected profit margin component that is recorded under business combination accounting principles. We believe the adjustment is useful to investors as an additional means to reflect cost of sales and gross margin trends of our business. |
| (3) Amortization of intangible assets and finance lease: Amortization of intangible assets and finance lease consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, an intangible asset in connection with a company-wide ERP system implementation, and one finance lease. We record expense relating to the amortization of these intangibles and finance lease in our GAAP financial statements. Amortization expenses for our intangible assets and finance lease are inconsistent in amount and are significantly impacted by the timing and valuation of an acquisition. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance. |
| (4) Transaction and integration costs, ERP implementation costs and unallocated legal fees: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. ERP implementation costs related to a company-wide ERP system implementation are expensed in our GAAP financial statements. Unallocated legal fees for transaction-related non-compete agreement disputes are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with each transaction and are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (5) Goodwill impairment: A goodwill impairment charge related to business formerly included in the Industrial Products segment is expensed in our GAAP financial statements. Management excludes this item for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding this item from our non-GAAP financial measures is useful to investors because this item is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (6) Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate. |
| (7) Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and six months ended June 30, 2021 and 2020, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities. |